IngentaConnect Long-term clearance of patch-stage mycosis fungoides with the 308...

Authors: Upjohn, E.; Foley, P.; Lane, P.¹; Magee, J.²; Prince, H. M.; McCormack, C.; Sinclair, R.

Source: Clinical & Experimental Dermatology, Volume 32, Number 2, March 2007 , pp. 168-171(4)

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$47.44 plus tax Refund Policy

More like this?

In this: publication
By this: publisher
In this Subject: Dermatology
By this author: Upjohn, E. ; Foley, P. ; Lane, P. ; Magee, J. ; Prince, H. M. ; McCormack, C. ; Sinclair, R.

Abstract:

Summary

In order to investigate the effectiveness of the 308-nm xenon chloride laser in the treatment of patch-stage mycosis fungoides that is refractory to topical steroids, we conducted a prospective, histologically controlled, open-label pilot study. Eight patients with stage 1A or 1B cutaneous T-cell lymphoma that was unresponsive to application of potent topical steroids received 20 treatments with the laser over 10 weeks and were then followed up for a minimum of 30 months. Three patients had a complete clinical and histological response and remained free of disease after 30 months A further three patients had complete clinical and histological clearance of disease, but experienced relapse within the 30 months follow-up period. One patient withdrew from the study and one had a partial response. Further research to establish the role of the 308-nm laser in the treatment of MF appears justified.

Document Type: Research article

DOI: 10.1111/j.1365-2230.2006.02308.x

Affiliations: 1: Skin and Cancer Foundation, Carlton, Victoria, Australia 2: Symbion Health, Heidelberg, Victoria, Australia

Long-term clearance of patch-stage mycosis fungoides with the 308-nm laser